SuperworthTaysha Gene Therapies shares outstanding TSHA
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 369M
- On a year earlier
- +23.8%
- more shares
Taysha Gene Therapies had 369M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 23.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 356.9M | +33% |
| FY2024 | 268.2M | +28% |
| FY2023 | 209.6M | +272% |
| FY2022 | 56.4M | +48% |
| FY2021 | 38.1M | +3% |
| FY2020 | 37M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 369M | +24% | |
| Q1 FY26 | 366.6M | +36% | |
| Q4 FY25 | 356.9M | +33% | |
| Q3 FY25 | 353.3M | +32% | |
| Q2 FY25 | 298M | +28% | |
| Q1 FY25 | 269.3M | +16% | |
| Q4 FY24 | 268.2M | +28% | |
| Q3 FY24 | 267.8M | +113% | |
| Q2 FY24 | 232.8M | +262% | |
| Q1 FY24 | 231.2M | +266% | |
| Q4 FY23 | 209.6M | +272% | |
| Q3 FY23 | 125.7M | +207% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Taysha Gene Therapies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.